{"schema_version":"secwatch.filing_event.v1","accession":"0001214659-23-004684","form_type":"8-K","ticker":"ALZN","cik":"0001677077","company_name":"Alzamend Neuro, Inc.","filed_at":"2023-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.993890+00:00","generated_at":"2026-06-17T07:04:19.933384+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Alzamend Neuro initiates Phase I/IIA trial of ALZN002 for mild to moderate Alzheimer's dementia","bullets":["Initiated Phase I/IIA clinical trial of immunotherapy vaccine ALZN002 for mild to moderate Alzheimer's dementia.","Primary goal: determine appropriate dose for Phase IIB trial; Phase IIB expected within 3 months of initial data.","Enrolling 20-30 subjects with mild to moderate morbidity; assesses safety, tolerability, efficacy vs placebo.","CEO states ALZN002 may limit infusions, reduce adverse reactions, and improve cognitive outcomes."],"urls":{"canonical":"https://secwatch.observer/filing/0001214659-23-004684","json":"https://secwatch.observer/filing/0001214659-23-004684.json","markdown":"https://secwatch.observer/filing/0001214659-23-004684.md","text":"https://secwatch.observer/filing/0001214659-23-004684.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677077/000121465923004684/0001214659-23-004684-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677077/000121465923004684/p412308k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:04:19.933384+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}